These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22577132)

  • 1. Commentary: Canadian Association for Population Therapeutics: the past, present and future - a personal viewpoint and a call to action.
    Rawson NS
    J Popul Ther Clin Pharmacol; 2011; 18(2):e403-6. PubMed ID: 22577132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology in the pharmaceutical Industry: A Canadian perspective.
    Rawson NS; De Souza LR
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):758-62. PubMed ID: 16832827
    [No Abstract]   [Full Text] [Related]  

  • 3. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutics.
    Platt R; Davis R; Finkelstein J; Go AS; Gurwitz JH; Roblin D; Soumerai S; Ross-Degnan D; Andrade S; Goodman MJ; Martinson B; Raebel MA; Smith D; Ulcickas-Yood M; Chan KA
    Pharmacoepidemiol Drug Saf; 2001; 10(5):373-7. PubMed ID: 11802579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical health promotion: a new concept in therapeutics.
    Mant A
    Soc Sci Med; 1994 Aug; 39(3):305-6. PubMed ID: 7939846
    [No Abstract]   [Full Text] [Related]  

  • 5. A national drug agency.
    West R; Borden EK; Collet JP; Rawson NS; Tonks RS
    CMAJ; 2003 Apr; 168(8):962-3. PubMed ID: 12695372
    [No Abstract]   [Full Text] [Related]  

  • 6. We need Romanow's National Drug Agency.
    CMAJ; 2003 Feb; 168(3):249, 251. PubMed ID: 12566321
    [No Abstract]   [Full Text] [Related]  

  • 7. Value in health: "bridging the gap" among our disciplines.
    Mauskopf J
    Value Health; 2003; 6(1):1-2. PubMed ID: 12535231
    [No Abstract]   [Full Text] [Related]  

  • 8. NICE to advise firms on how to speed up NHS adoption of their drugs.
    Hawkes N
    BMJ; 2015 May; 350():h2813. PubMed ID: 26002040
    [No Abstract]   [Full Text] [Related]  

  • 9. The ISPOR Good Practice Modeling Principles--a sensible approach: be transparent, be reasonable.
    Garrison LP
    Value Health; 2003; 6(1):6-8. PubMed ID: 12535233
    [No Abstract]   [Full Text] [Related]  

  • 10. Showcasing pharmaceutical economics, outcomes, and health policy: an update in clinical therapeutics.
    Lau DT
    Clin Ther; 2013 Apr; 35(4):354-5. PubMed ID: 23522659
    [No Abstract]   [Full Text] [Related]  

  • 11. Canadian hopes for low-cost drugs dashed.
    Kondro W
    Lancet; 1998 Jan; 351(9099):350. PubMed ID: 9652632
    [No Abstract]   [Full Text] [Related]  

  • 12. 25 years of pharmacoepidemiologic innovation: the Saskatchewan health administrative databases.
    Rawson NS; Downey W; Maxwell CJ; West R
    J Popul Ther Clin Pharmacol; 2011; 18(2):e245-9. PubMed ID: 22577131
    [No Abstract]   [Full Text] [Related]  

  • 13. An overview of pharmacoepidemiology in New Zealand: medical databases, registries and research achievements.
    Nishtala P; Ndukwe H; Chyou TY; Salahudeen M; Narayan S
    N Z Med J; 2017 Jan; 130(1449):52-61. PubMed ID: 28178730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating economic evaluations into decision-making: the Ontario experience.
    Laupacis A
    Med Care; 2005 Jul; 43(7 Suppl):15-9. PubMed ID: 16056004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada.
    Vandergrift M; Kanavos P
    Health Policy; 1997 Sep; 41(3):241-60. PubMed ID: 10170092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Centralising drug review to improve coverage decisions: economic lessons from (and for) Canada.
    Morgan S; McMahon M; Mitton C
    Appl Health Econ Health Policy; 2006; 5(2):67-73. PubMed ID: 16872248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2017 Dec; 2017():1-31. PubMed ID: 29361657
    [No Abstract]   [Full Text] [Related]  

  • 18. Access to linked administrative healthcare utilization data for pharmacoepidemiology and pharmacoeconomics research in Canada: anti-viral drugs as an example.
    Rawson NS
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1072-9. PubMed ID: 19650154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Foresight scanning: future directions of clinical and pharmaceutical research.
    Foster BC
    J Pharm Pharm Sci; 2008; 11(4):108s-22s. PubMed ID: 19183518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada.
    Int J Technol Assess Health Care; 1995; 11(4):796-7. PubMed ID: 8567213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.